ImmunoPrecise Antibodies (IPA) Revenue & Revenue Breakdown

OverviewOwnership Financials Chart Transcripts

ImmunoPrecise Antibodies Revenue Highlights

Latest Revenue (Y)

$20.66M

Latest Revenue (Q)

$6.22M

Main Segment (Y)

Project Revenue

Main Geography (Y)

UNITED STATES

ImmunoPrecise Antibodies Revenue by Period

ImmunoPrecise Antibodies Revenue by Year

Date	Revenue	Change
2023-04-30	$20.66M	6.72%
2022-04-30	$19.36M	8.11%
2021-04-30	$17.91M	27.42%
2020-04-30	$14.06M	28.66%
2019-04-30	$10.93M	100.80%
2018-04-30	$5.44M	106.85%
2017-04-30	$2.63M	38.73%
2016-04-30	$1.90M	7.51%
2014-12-31	$1.76M	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2011-12-31	-	100.00%
2010-12-31	-	100.00%
2009-12-31	-	100.00%
2008-12-31	-	100.00%
2007-12-31	-	100.00%
2006-12-31	-	100.00%
2005-12-31	-	100.00%
2004-12-31	-	100.00%
2003-12-31	-	100.00%
2002-12-31	-	-100.00%
2001-12-31	$386.00	16.97%
2000-12-31	$330.00	-95.65%
1999-12-31	$7.58K	-85.62%
1998-12-31	$52.73K	87785.00%
1997-12-31	$60.00	-99.08%
1996-12-31	$6.53K	-

ImmunoPrecise Antibodies generated $20.66M in revenue during NA 2022, up 6.72% compared to the previous quarter, and up 379.78% compared to the same period a year ago.

ImmunoPrecise Antibodies Revenue by Quarter

Date	Revenue	Change
2024-01-31	$6.22M	1.15%
2023-10-31	$6.15M	31.16%
2023-08-09	$4.69M	-16.58%
2023-04-30	$5.62M	8.70%
2023-01-31	$5.17M	-0.25%
2022-12-13	$5.18M	10.56%
2022-07-31	$4.69M	-10.50%
2022-04-30	$5.24M	8.81%
2022-01-31	$4.82M	1.97%
2021-10-31	$4.72M	2.92%
2021-07-31	$4.59M	-5.92%
2021-04-30	$4.88M	7.98%
2021-01-31	$4.52M	-5.02%
2020-10-31	$4.75M	26.28%
2020-07-31	$3.76M	-9.17%
2020-04-30	$4.15M	2.74%
2020-01-31	$4.03M	27.58%
2019-10-31	$3.16M	16.43%
2019-07-31	$2.72M	2.84%
2019-04-30	$2.64M	-2.02%
2019-01-31	$2.70M	-0.78%
2018-10-31	$2.72M	-5.43%
2018-07-31	$2.87M	58.65%
2018-04-30	$1.81M	5.07%
2018-01-31	$1.72M	30.92%
2017-10-31	$1.32M	122.70%
2017-07-31	$591.06K	-0.57%
2017-04-30	$594.45K	16.37%
2017-01-31	$510.83K	-35.97%
2016-10-31	$797.81K	9.68%
2016-07-31	$727.42K	100.00%
2016-03-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2012-09-30	-	100.00%
2012-06-30	-	100.00%
2011-09-30	-	100.00%
2011-06-30	-	100.00%
2010-09-30	-	100.00%
2010-03-31	-	100.00%
2009-09-30	-	100.00%
2009-06-30	-	-100.00%
2008-09-30	$131.55K	636.97%
2008-06-30	$17.85K	-20.67%
2007-09-30	$22.50K	100.00%
2007-03-31	-	100.00%
2006-09-30	-	100.00%
2006-03-31	-	-100.00%
2005-09-30	$11.22K	100.00%
2005-03-31	-	-100.00%
2004-09-30	$9.32K	129.01%
2004-06-30	$4.07K	100.00%
2003-09-30	-	100.00%
2003-03-31	-	100.00%
2002-09-30	-	100.00%
2002-06-30	-	100.00%
2001-09-30	-	-100.00%
2001-06-30	$138.00	13700.00%
2000-09-30	$1.00	-
2000-06-30	$1.00	-
1999-09-30	$1.00	-

ImmunoPrecise Antibodies generated $6.22M in revenue during Q3 2023, up 1.15% compared to the previous quarter, and up 120.00% compared to the same period a year ago.

ImmunoPrecise Antibodies Revenue Breakdown

ImmunoPrecise Antibodies Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Apr 24	Apr 23	Apr 22
Product Sales	$2.04M	$1.75M	$1.65M
Project Revenue	$22.23M	$18.68M	$17.36M

ImmunoPrecise Antibodies's latest annual revenue breakdown by segment (product or service), as of Apr 24: Project Revenue (91.62%), and Product Sales (8.38%).

Quarterly Revenue by Product

Product/Service	Apr 24
Product Sales	$2.04M
Project Revenue	$22.23M

ImmunoPrecise Antibodies's latest quarterly revenue breakdown by segment (product or service), as of Apr 24: Project Revenue (91.62%), and Product Sales (8.38%).

ImmunoPrecise Antibodies Revenue Breakdown by Country

Annual Revenue by Country

Country	Apr 24	Apr 23	Apr 22
Europe	$10.87M	$9.45M	$9.43M
AUSTRALIA	$482.00K	$630.00K	$1.54M
All Other Countries	$224.00K	$602.00K	$1.01M
CANADA	$389.00K	$618.00K	$572.00K
UNITED STATES	$12.56M	$9.37M	$6.82M

ImmunoPrecise Antibodies's latest annual revenue breakdown by geography, as of Apr 24: UNITED STATES (51.21%), Europe (44.32%), AUSTRALIA (1.97%), CANADA (1.59%), and All Other Countries (0.91%).

Quarterly Revenue by Country

Country	Apr 24
All Other Countries	$224.00K
UNITED STATES	$12.56M
Europe	$10.87M
CANADA	$389.00K
AUSTRALIA	$482.00K

ImmunoPrecise Antibodies's latest quarterly revenue breakdown by geography, as of Apr 24: UNITED STATES (51.21%), Europe (44.32%), AUSTRALIA (1.97%), CANADA (1.59%), and All Other Countries (0.91%).

ImmunoPrecise Antibodies Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
WVE	Wave Life Sciences	$113.31M	$19.69M
RXRX	Recursion Pharmaceuticals	$44.58M	$14.42M
TCRX	TScan Therapeutics	$21.05M	-
IPA	ImmunoPrecise Antibodies	$20.66M	$6.22M
CUE	Cue Biopharma	$5.49M	$3.34M
IPSC	Century Therapeutics	$2.23M	$791.00K
STTK	Shattuck Labs	$1.66M	$1.61M
TFFP	TFF Pharmaceuticals	$733.87K	$193.39K
ANEB	Anebulo Pharmaceuticals	-	-
ZURA	Zura Bio	-	-
AVTE	Aerovate Therapeutics	-	-
INAB	IN8bio	-	-
CGTX	Cognition Therapeutics	-	-
ANNX	Annexon	-	-
DRMA	Dermata Therapeutics	-	-
UBX	Unity Bio	-	-
AVIR	Atea Pharmaceuticals	-	-
CSBR	Champions Oncology	-	$-14.06M

IPA Revenue FAQ

What is ImmunoPrecise Antibodies’s yearly revenue?

ImmunoPrecise Antibodies's yearly revenue for 2022 was $20.66M, representing an increase of 6.72% compared to 2021. The company's yearly revenue for 2021 was $19.36M, representing an increase of 8.11% compared to 2020. IPA's yearly revenue for 2020 was $17.91M, representing an increase of 27.42% compared to 2019.

What is ImmunoPrecise Antibodies’s quarterly revenue?

ImmunoPrecise Antibodies's quarterly revenue for Q3 2023 was $6.22M, a 1.15% increase from the previous quarter (Q2 2023), and a 20.31% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $6.15M, a 31.16% increase from the previous quarter (Q1 2023), and a 18.63% increase year-over-year (Q2 2022). IPA's quarterly revenue for Q1 2023 was $4.69M, a -16.58% decrease from the previous quarter (Q4 2022), and a 0% increase year-over-year (Q1 2022).

What is ImmunoPrecise Antibodies’s revenue growth rate?

ImmunoPrecise Antibodies's revenue growth rate for the last 3 years (2020-2022) was 15.37%, and for the last 5 years (2018-2022) was 89.13%.

What are ImmunoPrecise Antibodies’s revenue streams?

ImmunoPrecise Antibodies's revenue streams in r 24 are Product Sales, and Project Revenue. Product Sales generated $2.04M in revenue, accounting 8.38% of the company's total revenue, up 16.49% year-over-year. Project Revenue generated $22.24M in revenue, accounting 91.62% of the company's total revenue, up 19.05% year-over-year.

What is ImmunoPrecise Antibodies’s main source of revenue?

For the fiscal year ending Apr 24, the largest source of revenue of ImmunoPrecise Antibodies was Project Revenue. This segment made a revenue of $22.24M, representing 91.62% of the company's total revenue.